HIV: First pediatric vaccination of Vertically Infected Children in Italy - First Pediatric Randomised Trial (PEDVAC).
A pediatric vaccination was successfully tested on twenty vertically HIV-infected children, 6–16 years of age, with stable viral load control and CD4+ values above 400 cells/mm3, at the Pediatric Hospital of the Child Jesus in Rome.
The research is published on PLOS one and it was led by immunologist Paolo Palma, from Paolo Rossi’s team.
Ten subjects continued their ongoing antiretroviral treatment (ART) and ten were immunized with a HIV-DNA vaccine in addition to their previous therapy (ART and vaccine). The genetic vaccine represented HIV-1 subtypes A, B and C, encoded Env, Rev, Gag and RT and had no additional adjuvant. Immunizations took place at weeks 0, 4 and 12, with a boosting dose at week 36. Monitoring was performed until week 60 and extended to week 96.
The study demonstrates the feasibility, safety and moderate immunogenicity of genetic vaccination in vertically HIV-infected children, paving the way for amplified immunotherapeutic approaches in the pediatric population.
To read more: PLOS one link.